The Montreal-area CRO escaped the commodity economics of generic-drug testing by stitching labs, clinics and manufacturing into one early-development platform. Its wager is simple: the science need not move recklessly for the program to move faster.
Vivodyne is a biotech company that grows more than 20 types of lifelike human organ tissues in the lab, then uses robotic automation to dose, cultivate, and analyze more than 10,000 of them at a time. The vast human datasets it generates feed multimodal AI models that predict how new drugs will behave in people - before they ever reach a clinical trial. The pitch is blunt: roughly 95% of therapies that work in animal models fail in human trials, and Vivodyne wants to fix that gap with real human data instead of mice.